Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Given Consensus Recommendation of “Buy” by Brokerages

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) has been assigned an average rating of “Buy” from the twelve ratings firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, eight have assigned a buy rating and three have issued a strong buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $30.3333.

A number of research firms have recently issued reports on MNMD. Lifesci Capital upgraded Mind Medicine (MindMed) to a “strong-buy” rating in a research note on Tuesday, October 14th. Royal Bank Of Canada decreased their price target on Mind Medicine (MindMed) from $21.00 to $20.00 and set an “outperform” rating for the company in a report on Friday, November 7th. Chardan Capital raised shares of Mind Medicine (MindMed) to a “strong-buy” rating in a research report on Wednesday, November 19th. Needham & Company LLC set a $28.00 price objective on shares of Mind Medicine (MindMed) and gave the company a “buy” rating in a research note on Monday, October 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Mind Medicine (MindMed) in a research report on Wednesday, October 8th.

Mind Medicine (MindMed) News Roundup

Here are the key news stories impacting Mind Medicine (MindMed) this week:

• Positive Sentiment: MM‑120 moved into Phase III for GAD and MDD with pivotal readouts expected in 2026 — a clear near‑term clinical catalyst that supports upside expectations for the stock. Read More.
• Positive Sentiment: Broker and analyst enthusiasm (including recent buy/strong‑buy coverage and a handful of high targets) is lifting sentiment and provides potential support for the stock ahead of clinical readouts. Read More.
• Neutral Sentiment: Analyst/ownership mix is mixed: consensus ratings skew positive with an elevated average price target, while institutional ownership (~28%) gives market credibility but also means larger holders could add to volatility. Read More.
• Negative Sentiment: Clustered insider selling on Dec. 26 — CEO Robert Barrow (25,791 shares), Mark Sullivan (11,276 shares) and Daniel Karlin (5,600 shares) — has introduced immediate selling pressure and is the most direct reason cited for the stock trading down today. Read More.
• Negative Sentiment: Fundamental headwinds remain — recent quarterly results missed estimates and analysts model negative EPS for the year, which increases sensitivity to execution and clinical outcomes. Read More.

Mind Medicine (MindMed) Price Performance

Mind Medicine (MindMed) stock opened at $12.95 on Friday. The company has a quick ratio of 3.30, a current ratio of 3.30 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $1.28 billion, a P/E ratio of -6.35 and a beta of 2.57. The firm has a fifty day moving average of $12.34 and a 200-day moving average of $10.51. Mind Medicine has a 52-week low of $4.70 and a 52-week high of $14.43.

Mind Medicine (MindMed) (NASDAQ:MNMD) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.26). As a group, analysts predict that Mind Medicine will post -1.35 EPS for the current year.

Insider Buying and Selling at Mind Medicine (MindMed)

In related news, insider Daniel Karlin sold 5,600 shares of the business’s stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $73,640.00. Following the transaction, the insider owned 425,025 shares in the company, valued at approximately $5,589,078.75. The trade was a 1.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Mark Sullivan sold 11,276 shares of the firm’s stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $148,279.40. Following the sale, the insider owned 282,576 shares of the company’s stock, valued at approximately $3,715,874.40. This trade represents a 3.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 42,667 shares of company stock valued at $561,071 in the last ninety days. Insiders own 2.26% of the company’s stock.

Hedge Funds Weigh In On Mind Medicine (MindMed)

A number of institutional investors have recently made changes to their positions in the business. Commodore Capital LP grew its position in shares of Mind Medicine (MindMed) by 10.5% during the second quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock worth $32,450,000 after buying an additional 475,000 shares in the last quarter. Marshall Wace LLP grew its holdings in Mind Medicine (MindMed) by 31.9% during the 2nd quarter. Marshall Wace LLP now owns 3,421,224 shares of the company’s stock worth $22,204,000 after acquiring an additional 828,067 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Mind Medicine (MindMed) by 11.0% in the 3rd quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock worth $23,732,000 after purchasing an additional 198,878 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Mind Medicine (MindMed) by 4.0% in the 2nd quarter. Geode Capital Management LLC now owns 1,733,454 shares of the company’s stock valued at $11,252,000 after purchasing an additional 66,663 shares in the last quarter. Finally, AWM Investment Company Inc. lifted its position in shares of Mind Medicine (MindMed) by 0.6% during the second quarter. AWM Investment Company Inc. now owns 1,215,662 shares of the company’s stock worth $7,890,000 after purchasing an additional 7,500 shares during the last quarter. 27.91% of the stock is owned by institutional investors and hedge funds.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) is a clinical-stage biopharmaceutical company focused on developing psychedelic-inspired therapies to address a range of mental health and neurological disorders. The company applies traditional drug development techniques to molecules derived from psychedelic compounds, with an emphasis on safety, efficacy and scalable manufacturing. Its research and development activities span small-molecule analogues, novel formulations and digital therapeutics designed to enhance or support pharmacological interventions.

The company’s lead development programs include MM-120, an investigational low-dose LSD formulation intended for treatment of anxiety; MM-310, an ibogaine-derived non-hallucinogenic compound targeting opioid withdrawal and addiction; and MM-402, a proprietary 5-MeO-DMT receptor agonist for mood and stress-related indications.